Browsing by Author Jonker, Derek J.

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 9 of 9
Issue DateTitleAuthor(s)Citation
2010Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With CetuximabSimes, Robert John; Arena, Sabrina; Bardelli, Alberto; Cutsem, E Van; De Roock, Wendy; Di Nicolantonio, Federica; Frattini, Milo; Jonker, Derek J.; Karapetis, Christos; Khambata-Ford, Shirin; Lamba, Simona; O'Callaghan, Chris; Piessevaux, Hubert; Sartore-Bianchi, Andrea; Siena, Salvatore; Tejpar, Sabine; Tu, D.; Zalcberg, John; School of Public Health: NH&MRC Clinical Trials CentreAssociation of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab, JAMA: The Journal of the American Medical Association, vol.304, 16,pp 1812-1820
2007Cetuximab for the Treatment of Colorectal CancerSimes, Robert John; Zalcberg, John; Au, Heather Jane; Berry, Scott R.; et, al; Jonker, Derek J.; Karapetis, Christos (Chris); Krahn, Marianne; O’Callaghan, Chris J.; Price, Timothy; Tebbutt, Niall C; Tu, Dongsheng; van Hazel, Guy; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreCetuximab for the Treatment of Colorectal Cancer, New England Journal of Medicine, vol.357,(20),2007,pp 2040-2048
2016Effects of a Structured Exercise Program on Physical Activity and Fitness in Colon Cancer Survivors: One Year Feasibility Results from the CHALLENGE TrialDhillon, Haryana; Turner, Jane; Vardy, Janette; Campbell, Kristen L.; Chua, Neil; Courneya, Kerry S.; Crawford, Jennifer J; et al, Various; Friedenreich, Christine; Jonker, Derek J.; O'Brien, Patti; O'Callaghan, Christopher J.; Prapavessis, Harry; Psychology; Western Clinical School: Medicine (Westmead); Concord Clinical School: MedicineEffects of a Structured Exercise Program on Physical Activity and Fitness in Colon Cancer Survivors: One Year Feasibility Results from the CHALLENGE Trial, Cancer Epidemiology, Biomarkers and Prevention, vol.25, 6, 2016,pp 969-977
2014Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancerSimes, Robert John; et al, Various; Harbison, C; Jonker, Derek J.; Karapetis, Christos (Chris); Langer, C; Malone, DP; O’Callaghan, C; Price, Timothy; Shapiro, J; Tebbutt, Niall; Tu, Dongsheng; School of Public Health: NH&MRC Clinical Trials CentreEpiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer, British Journal of Cancer, vol.110, 3, 2014,pp 648-655
2013Phase III Randomized, Placebo-Controlled Study of Cetuximab Plus Brivanib Alaninate Versus Cetuximab Plus Placebo in PatientsWith Metastatic, Chemotherapy-Refractory, Wild-TypeK-RASColorectal Carcinoma: The NCIC Clinical Trials Group and AGITG CO.20 TrialSimes, Robert John; Zalcberg, John; Charpentier, Danielle; Couture, Felix; et al, Various; Jonker, Derek J.; Karapetis, Christos (Chris); Moore, Malcolm; Nott, Louise M; Price, Timothy; Shapiro, Jeremy; Siddiqui, Jehan; Siu, Lillian L; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentrePhase III Randomized, Placebo-Controlled Study of Cetuximab Plus Brivanib Alaninate Versus Cetuximab Plus Placebo in PatientsWith Metastatic, Chemotherapy-Refractory, Wild-TypeK-RASColorectal Carcinoma: The NCIC Clinical Trials Group and AGITG CO.20 Trial, Journal of Clinical Oncology, vol.31, 19, 2013,pp 2477-2484
2009Prospective Cost-Effectiveness Analysis of Cetuximab in Metastatic Colorectal Cancer: Evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 TrialSimes, Robert John; Tebbutt, Niall; Zalcberg, John; Au, Heather-Jane; Australasian Gastrointestinal Interest, Group; Colwell, Bruce; Evans, William K.; Findlay, Brian; Gibbs, Peter; Isogai, Pierre K.; Jonker, Derek J.; Karapetis, Christos; Links, Matthew; Mittman, Nicole; Moore, Malcolm; O'Callaghan, Chris; Siddiqui, Jehan; Tu, D.; Working Group on Economic Analysis of the National Cancer Institute of Canada, Clinical Trials Group; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreProspective Cost-Effectiveness Analysis of Cetuximab in Metastatic Colorectal Cancer: Evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 Trial, Journal of the National Cancer Institute, vol.101, 17, 2009,pp 1182-1192
2014Quality of life in patients with K-RAS wild-type colorectal cancer: the CO.20 phase 3 randomized trialEl-Tahche, Fabyolla; Shannon, Jenny; Alcindor, Thierry; Au, Heather-Jane; Easaw, Jay C; et al, Various; Jeffery, Mark; Jonker, Derek J.; Kotb, Rami; Moore, Malcolm; Ng, Siobhan; Ringash, Jolie; Sabesan, Sabe; Salim, Muhammad; Shapiro, Jeremy; Siu, Lillian L; Strickland, A. H.; Zalcberg, John; Central Clinical School: Medicine; Nepean Clinical School: MedicineQuality of life in patients with K-RAS wild-type colorectal cancer: the CO.20 phase 3 randomized trial, Cancer, vol.120, 2, 2014,pp 181-189
2014The relationship between rash, tumour KRAS mutation status and clinical and quality of life outcomes in patients with advanced colorectal cancer treated with cetuximab in the NCIC CTG/AGITG CO.17Simes, Robert John; Sommeijer, Dirkje; Jonker, Derek J.; Karapetis, Christos; O’CALLAGHAN, Chris; Price, Timothy; Tebbutt, Niall; Tu, Dongsheng; Yip, Desmond; Zalcberg, John; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreThe relationship between rash, tumour KRAS mutation status and clinical and quality of life outcomes in patients with advanced colorectal cancer treated with cetuximab in the NCIC CTG/AGITG CO.17, Acta Oncologica, vol.53, 7, 2014,pp 877-884
2016Significance of baseline and change in quality of life scores in predicting clinical outcomes in an international phase III trial of advanced pancreatic cancer: NCIC CTG PA.3Lee, Chee Khoon; Au, Heather Jane; Brundage, M.D.; Goldstein, David; Jonker, Derek J.; Moore, Malcolm J.; O'Callaghan, Chris J.; Parulekar, Wendy R.; Ringash, Jolie; Tu, Dongsheng; Vickers, Michael M.; Wheatley-Price, Paul; NH&MRC Clinical Trials CentreSignificance of baseline and change in quality of life scores in predicting clinical outcomes in an international phase III trial of advanced pancreatic cancer: NCIC CTG PA.3, Pancreatology, vol.16, 6, 2016,pp 1106-1112